

PSPN/GFR α 4 has a significantly weaker capacity than GDNF/GFR α 1 to recruit RET to rafts, but promotes neuronal survival and neurite outgrowth[☆]

Jianmin Yang^a, Maria Lindahl^a, Päivi Lindholm^a, Heidi Virtanen^a, Eleanor Coffey^b, Pia Runeberg-Roos^a, Mart Saarma^{a,*}

^aInstitute of Biotechnology, Viikki Biocenter, University of Helsinki, Viikinkaari 9, P.O. Box 56, FIN-00014 Helsinki, Finland

^bTurku Centre for Biotechnology, Åbo Akademi and Turku University, FIN-20521 Turku, Finland

Received 5 April 2004; revised 25 May 2004; accepted 2 June 2004

Available online 15 June 2004

Edited by Gerrit van Meer

Abstract Previously, it was shown that the recruitment of RET into lipid rafts by glial cell line-derived neurotrophic factor (GDNF)/GFR α 1 is crucial for efficient signal transduction. Here, we show that the mouse GFR α 4 is a functional, N-glycosylated, glycosylphosphatidylinositol (GPI)-anchored protein, which mediates persephin (PSPN)-induced phosphorylation of RET, but has an almost undetectable capacity to recruit RET into the 0.1% Triton X-100 insoluble membrane fraction. In spite of this, PSPN/mGFR α 4 promotes neurite outgrowth in PC6-3 cells and survival of cerebellar granule neurons. As we show that also human PSPN/GFR α 4 is unable to recruit RET into lipid rafts, we propose that the mammalian GFR α 4 in this respect differs from GFR α 1.

© 2004 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Keywords: GFR α 4; Persephin; RET; Cell survival; Neurite outgrowth; Raft

1. Introduction

The glial cell line-derived neurotrophic factor (GDNF), neurturin (NRTN), artemin (ARTN) and persephin (PSPN) are GDNF family ligands (GFLs) involved in the differentiation, development, and survival of neurons. These structurally related neurotrophic factors can support the survival of dopamine neurons and motoneurons, and are thus potential therapeutic agents for neurodegenerative diseases [1]. Each of these neurotrophic factors preferentially binds to one of the glycosylphosphatidylinositol (GPI)-anchored GDNF family receptors α (GFR α). GDNF binds to GFR α 1, NRTN to GFR α 2, ARTN to GFR α 3 and PSPN to GFR α 4. The GFL-activated GFR α receptors all signal through the receptor tyrosine kinase RET [1]. In the presence of GDNF, GFR α 1 recruits RET into lipid rafts. The recruitment of RET into lipid rafts has previously been shown to be required for

downstream signalling, differentiation and neuronal survival [2–4].

The chicken GFR α 4 was the first identified receptor for PSPN [5,6]. Later GFR α 4 receptors were characterised in human [7], rat [8] and mouse [9]. PSPN does not cross-activate RET through GFR α 1 and GDNF does not cross-activate RET through GFR α 4 [7,8]. The mammalian GFR α 4 receptors all lack the first N-terminal Cys-rich domain, have short C-terminal hinge regions and thereby differ in structure from the other GFR α receptors, including the chicken GFR α 4. In spite of this structural difference, the human GPI-anchored GFR α 4 promotes PSPN-dependent survival of sympathetic neurons when co-microinjected with RET [7].

The structure and expression of the mouse *Gfra4* (*mGfra4*) have been characterised [9], but the functionality of this receptor has not been studied. Here, we characterise the basic biochemical and cell-biological features of this receptor, and show that PSPN/GFR α 4 contrary to the previously described GDNF/GFR α 1 fails to recruit RET to lipid rafts upon ligand stimulation.

2. Materials and methods

2.1. Constructs, transfections and cell lines

The cDNAs encoding mouse *Gfra4*-FLAG with an N-terminal FLAG-tag and rat *Gfra1* were cloned into pcDNA3. The cDNAs encoding human short isoform of RET (in pBabePuro) and human long isoform of RET (in pCR3.1) were gifts from Marc Billaud. Neuro 2a cells (ATCC) were transfected with FuGene 6 (Roche Molecular Biochemicals), PC6-3 cells [10] with Lipofectamine 2000 (Invitrogen), and rat primary cerebellar granule neurons with the calcium phosphate method [11]. The stable Neuro 2a cell line expressing rat *Gfra1* was a gift from Marc Billaud and the Neuro 2a cell line expressing human *GFR α 4* has been described by Lindahl et al. [7]. The Neuro 2a cell line stably expressing mouse *Gfra4*-FLAG was generated under G418 selection.

2.2. Antibodies

In this work, we used antibodies to FLAG (M2, Sigma, 1:1500), GFR α 1 (PProSci, 1:500), RET (Santa Cruz Biotechnology Inc., C-19 or C-20, 1:500), phosphotyrosine (4G10, Upstate Biotechnology, 1:1500), and transferrin receptor (Zymed Laboratories Inc., 1:500).


2.3. Glycosylation assay

Stably transfected Neuro 2a cells were cultured with tunicamycin (Sigma) at 5 μ g/ml for 16 h. The cells were lysed on ice in lysis buffer (TBS, pH 7.5, 0.2 mM EDTA, 1% Nonidet P-40, 1% Triton X-100,

[☆] Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.febslet.2004.06.007.

* Corresponding author. Fax: +358-9-191-59366.

E-mail address: mart.saarma@helsinki.fi (M. Saarma).



1 mM PMSF, complete Mini EDTA-free protease inhibitor cocktail, Roche). The post nuclear supernatant (PNS) was analysed by Western blotting with antibodies to FLAG.

2.4. Membrane association assays

Stably transfected Neuro 2a cells were homogenised in 20 mM HEPES, pH 7.5, 0.25 mM sucrose, 1 mM EDTA, 1 mM PMSF, and complete Mini EDTA-free protease inhibitor cocktail, with a syringe. The PNS was mixed with 67% sucrose to give a final concentration of 60% sucrose. The sample was centrifuged in a gradient of 0.5 ml of 67%, 0.5 ml of 60%, 8.0 ml of 50% and 1.0 ml of 5% sucrose (Beckman SW41 rotor; 35000 rpm; 8 h; +4 °C). Fractions of 0.5 ml were collected from the top and analysed by Western blotting with antibodies to FLAG. The phosphatidylinositol-specific phospholipase C (PI-PLC) treatments were performed with 1 U/ml of PI-PLC (Sigma), for 40 min, in PBS, at 37 °C. Biotinylation of cell surface proteins with Sulfo-NHS-Biotin (Pierce) was done according to the manufacturer's instructions.

2.5. Binding and crosslinking assays

Human PSPN (PeproTech EC Ltd) was ¹²⁵I-labelled with the lactoperoxidase method and the binding assay as well as crosslinking assay were performed on transiently and stably transfected Neuro 2a cells as described earlier [7].

2.6. Phosphorylation assay of RET

Stably transfected Neuro 2a cells were starved for 4 h in serum-free DMEM at +37 °C and then stimulated with 0–100 ng/ml PSPN for 10 min at +37 °C. Parental Neuro 2a cells were stimulated with 0–100 ng/ml GDNF or PSPN (PeproTech EC Ltd.). RET-associated immunocomplexes were collected with Protein G Sepharose (Amersham Pharmacia Biotech) beads and analysed by Western blotting with antibodies to phosphotyrosine and RET.

2.7. Neuronal survival and neurite outgrowth assays

Cerebellar granule neurons (CGNs) were isolated from postnatal day 7 (P7) rats [12]. On day 5, the cultured neurons were transfected using the calcium phosphate method. After transfection (24 h), the neurons were transferred to serum-free low potassium medium (5 mM) in the presence or absence of PSPN (100 ng/ml). The number of rescued neurons was counted 2.5 days later. As one control, the number of rescued cells was compared to the number of viable cells maintained in high potassium medium (25 mM). As another control, the cells were transfected with *Gfra1* and *RET* and supported by GDNF (100 ng/ml).

Fig. 1. Characterisation of the FLAG-tagged mouse GFR α 4 receptor. (A) Western blot analysis of stably transfected Neuro 2a cells. The lysate from naive Neuro 2a cells is shown in lane 1. The FLAG-tagged mGFR α 4 is detected with molecular weights of 31 and 33 kD (lane 3). In the presence of tunicamycin, only the 31 kD band of mGFR α 4 is detectable (lane 2). (B) Membrane association of the mGFR α 4. Membranes from Neuro 2a cells expressing GFR α 4 were floated on a sucrose gradient. The fractions were collected and numbered from the top, separated on SDS-PAGE and analysed by Western blot with antibodies to FLAG. (C) Characterisation of the GPI-anchor of the mGFR α 4. Western blot analysis of the cell lysates (lanes 1–2) and media (lanes 3–4) from Neuro 2a cells stably expressing the mGFR α 4 receptor, before (lanes 1 and 3) or after (lanes 2 and 4) PI-PLC treatment. (D) Biotinylation of cell surface proteins of Neuro 2a cells stably transfected with *Gfra4*. As a control, an extract from cells expressing GFR α 4 was precipitated with streptavidin, without any preceding biotinylation (lane 1). An extract of biotinylated cells expressing the mGFR α 4 is shown in lane 2. (E) Crosslinking of ¹²⁵I-PSPN to Neuro 2a cells transiently transfected with either *mGfra4*-FLAG or human *GFR α 4*. After crosslinking, RET was immunoprecipitated from the cell extracts, the precipitate was run on a SDS-PAGE and visualised by autoradiography. (F) Dose-dependent phosphorylation of RET in Neuro 2a cells stably transfected with *mGFR α 4*. RET was immunoprecipitated from the cell extracts, and its phosphorylation was monitored on Western blots with antibodies to phosphotyrosine, the blot was reprobed with antibodies to RET. (G) Dose-dependent phosphorylation of RET induced by GDNF in naive Neuro 2a cells. The assay was done as above, except for the induction which was done with GDNF.

in 5 mM potassium. Neurite outgrowth was monitored in transiently transfected PC6-3 cells, 4–5 days after the addition of GDNF or PSPN (100 ng/ml).

2.8. Localisation of RET and mGFR α receptors to lipid rafts

Stably transfected Neuro 2a cells were stimulated with GDNF or PSPN (100 ng/ml) as described for the phosphorylation assay. The cells were collected into cold isotonic lysis buffer and homogenised with a syringe. After addition of 0.1% Triton X-100 to the PNS, the samples were kept on ice for 20 min and analysed on OptiPrep density gradients (0.9 ml 35%, 4.0 ml 30%, and 0.2 ml 0%) as described by Tansey et al. [2]. Fractions of 0.5 ml were collected from the top and analysed by Western blotting.

3. Results

3.1. The mouse GFR α 4 is a functional PSPN receptor

Sequence analysis of a putative GFR α 4 receptor from mouse predicted a protein of 260 amino acids, harbouring a hydrophobic ER signal sequence, one glycosylation site and a C-terminal GPI-anchor sequence [9]. The predicted molecular weight of this putative mouse PSPN receptor is 29 kD. Our Western blot analysis of Neuro 2a cells, stably transfected with FLAG-tagged *mGfra4*, shows the tagged protein with molecular weights of 31 and 33 kD, respectively. Tunicamycin treatment of the cells shows that the 31 kD band is a non-glycosylated precursor of the glycosylated, mature 33 kD FLAG-tagged mGFR α 4 (Fig. 1A).

To study the membrane association of the putative mGFR α 4, the cell lysate was analysed on a sucrose gradient, where membranes and proteins bound to the membranes become located in the top fraction. Western blot analysis of the fractions shows that the FLAG-tagged mGFR α 4 is located in the top fractions (Fig. 1B). PI-PLC treatment of stably transfected Neuro 2a cells expressing the FLAG-tagged *mGfra4* released the mouse GFR α 4 protein from the cell surface and we therefore conclude that the glycosylated 33 kD mGFR α 4 is located on the cell surface, where it is bound to the membrane by a functional GPI-anchor (Fig. 1C). The cell surface localisation was further verified by biotinylation of cell surface proteins (Fig. 1D).

To determine whether this putative mouse PSPN receptor directly interacts with PSPN and RET, we used 125 I-PSPN and Neuro 2a cells that endogenously express RET and were transfected with mGFR α 4. The binding of 125 I-PSPN to these cells could be specifically blocked with unlabelled PSPN, and the K_d was 2 nM (data not shown). Crosslinking of cell surface proteins to 125 I-PSPN and immunoprecipitation with antibodies to RET revealed two major radioactive bands, which could be displaced with unlabelled PSPN. The molecular weight of these bands could correspond to GFR α 4-PSPN and GFR α 4-PSPN-RET complexes, respectively (Fig. 1E and Supplementary Fig. 1).

To study if the mGFR α 4 receptor mediates signalling via RET, we monitored the phosphorylation of RET in Neuro 2a cells transfected with *mGfra4* and stimulated with PSPN. After immunoprecipitation of the samples with antibodies to RET and staining of the filters with antibodies to phosphotyrosine, we detected a clear dose-dependent phosphorylation of RET (Fig. 1F). PSPN does not mediate phosphorylation of RET in untransfected Neuro 2a cells (Supplementary Fig. 2). GDNF on the other hand mediates a clear and distinct phosphorylation of RET in untransfected Neuro 2a cells, directly

purchased from the ATCC (Fig. 1G). The presence of an endogenous GFR α 1 receptor and the absence of an endogenous GFR α 4 receptor in these cells was verified by PCR (data not shown).

3.2. The GFR α 4 receptor recruits RET to rafts very weakly

To set up the flotation assay, we used the previously characterised transferrin receptor, GFR α 1, and RET as markers [2]. The transferrin receptor (TFR) was used as a marker for Triton X-100 soluble fractions, whereas GPI-anchored GFR α 1 was used as a marker for Triton X-100 insoluble fractions (Fig. 2). Although GDNF/GFR α 1 induced a clear re-localisation of RET into the insoluble fraction, PSPN/GFR α 4 very weakly recruited RET into this fraction (Fig. 2). As the result was completely unexpected, we included the following controls. First, we verified the PSPN-dependent phosphorylation of RET by splitting the samples and using the other half of them for phosphorylation assays (Fig. 1F, and Supplementary Fig. 3). Second, we confirmed that the addition of the ligands




Fig. 2. Density gradient analysis of detergent insoluble membrane fractions. Neuro 2a extracts were analysed in the presence of 0.1% Triton X-100. Parental Neuro 2a cells are marked as untransfected. The transfected construct, the addition of ligand and the antibodies used for Western blotting to detect the GFR α 1 receptor, RET, FLAG or transferrin receptor (TFR), are indicated on the right. Nine fractions from each gradient are shown. The Triton X-100 insoluble top fraction is shown on the left as the fraction number 1.

mGFR α 4 receptor in transiently transfected PC6-3 cells, which endogenously express RET at a very low level (data not shown). After co-transfection with *Gfra1/RET* or *Gfra4/RET*, respectively, both GDNF and PSPN induced a clear network of neurites (Fig. 4B and C).

4. Discussion

Here, we show that PSPN/GFR α 4 recruits RET to the raft fraction very weakly although PSPN/GFR α 4 can stimulate both neurite outgrowth and neuronal survival. Previously, it was suggested that the recruitment of RET into lipid rafts by GDNF/GFR α 1 is required for downstream signalling, differentiation and neuronal survival [2].

An artificial transmembrane GFR α 1 (GFR α 1-TM) was earlier characterised in Neuro 2a cells where it was shown to mediate a strong GDNF-induced phosphorylation of RET, but was located outside the raft fraction. In spite of its full capacity to mediate the phosphorylation of RET, this transmembrane receptor mediated only attenuated neuronal differentiation and survival [2]. However, as we show here that Neuro 2a cells endogenously express GFR α 1, which mediates the phosphorylation of RET in untransfected cells, it is evident that the functionality of the GFR α 1-TM would need further examinations. The importance of the recruitment of RET into lipid rafts was also previously studied with the aid of a commercially available soluble GFR α 1 [4]. The biological activity of this receptor is routinely tested by the manufacturer by assaying its ability to mediate GDNF-induced neurite outgrowth in PC12 cells. Interestingly, the GDNF-activated soluble GFR α 1 receptor was inducing a less robust recruitment of RET to lipid rafts than the GDNF-activated GPI-anchored GFR α 1 receptor [4].

The GPI-anchored mouse GFR α 4 receptor is for some reason not as tightly associated with the raft fraction as the GPI-anchored GFR α 1. Because comparing results with different detergents in different cell lines was shown to be difficult [16], we used the same conditions to show that the localisation of the two different GFR α receptors, as well as their capacity to re-localise RET in the Triton X-100 soluble/insoluble fractions differ. The localisation of proteins in different fractions has been proposed to depend not only on protein–lipid interactions, but also on protein–protein interactions [17]. As the structure of the mammalian GFR α 4 significantly differs from GFR α 1, we propose that GFR α 1 and GFR α 4 interact differently with cell surface proteins. Thus, it is possible that our results with the two GPI-anchored GFR α receptors reflect their differential interaction with other cell surface proteins.

With the similar method which we used here, phosphorylated RET has been detected both outside and inside the raft fraction after GDNF/GFR α 1 stimulation [4]. Therefore, it is

evident that we in our work with GFR α 4 could not use the localisation of phosphorylated RET as an indication of whether PSPN/GFR α 4 activates RET inside or outside the rafts. Moreover, the general significance of the content of different detergent insoluble membrane fractions has recently been very thoroughly questioned [18]. In light of our results, it is at least clear that a robust recruitment of RET to the lipid rafts cannot always and tightly be correlated with the biological activity of a GFR α receptor.

Acknowledgements: We thank Satu Åkerberg and Mari Heikkinen for excellent technical assistance, Johan Peränen for helpful discussions during the work and Timo Pääväranta for rapid processing of the figures. This work was supported by the Academy of Finland, the Sigrid Jusélius Foundation and the EU Grant QLG3-CT-2002-01000.

References

- [1] Airaksinen, M.S. and Saarma, M. (2002) *Nat. Rev. Neurosci.* 3, 383–394.
- [2] Tansey, M.G., Baloh, R.H., Milbrandt, J. and Johnson Jr., E.M. (2000) *Neuron* 25, 611–623.
- [3] Encinas, M., Tansey, M.G., Tsui-Pierchala, B.A., Comella, J.X., Milbrandt, J. and Johnson Jr., E.M. (2001) *J. Neurosci.* 21, 1464–1472.
- [4] Paratcha, G., Ledda, F., Baars, L., Culpier, M., Besset, V., Anders, J., Scott, R. and Ibáñez, C.F. (2001) *Neuron* 29, 171–184.
- [5] Enokido, Y., de Sauvage, F., Hongo, J.A., Ninkina, N., Rosenthal, A., Buchman, V.L. and Davies, A.M. (1998) *Curr. Biol.* 8, 1019–1022.
- [6] Thompson, J., Doxakis, E., Piñon, L.G., Strachan, P., Buj-Bello, A., Wyatt, S., Buchman, V.L. and Davies, A.M. (1998) *Mol. Cell. Neurosci.* 11, 117–126.
- [7] Lindahl, M., Poteryaev, D., Yu, L., Arumäe, U., Timmusk, T., Bongarzone, I., Aiello, A., Pierotti, M.A., Airaksinen, M.S. and Saarma, M. (2001) *J. Biol. Chem.* 276, 9344–9351.
- [8] Masure, S., Cik, M., Hoefnagel, E., Nosrat, C.A., Van der Linden, I., Scott, I.R., Van Gompel, P., Lesage, A.S., Verhasselt, P., Ibáñez, C.F. and Gordon, R.D. (2000) *J. Biol. Chem.* 275, 39427–39434.
- [9] Lindahl, M., Timmusk, T., Rossi, J., Saarma, M. and Airaksinen, M.S. (2000) *Mol. Cell. Neurosci.* 15, 522–533.
- [10] Pittman, R.N., Wang, S., DiBenedetto, A.J. and Mills, J.C. (1993) *J. Neurosci.* 13, 3669–3680.
- [11] Craig, A.M. (1998) *Culturing Nerve Cells*, 2nd ed. The MIT Press, Cambridge, MA, pp. 79–111.
- [12] Miller, T.M. and Johnson Jr., E.M. (1996) *J. Neurosci.* 16, 7487–7495.
- [13] D’Mello, S.R., Galli, C., Ciotti, T. and Calissano, P. (1993) *Proc. Natl. Acad. Sci. USA* 90, 10989–10993.
- [14] Bilak, M.M., Shifrin, D.A., Corse, A.M., Bilak, S.R. and Kuncel, R.W. (1999) *Mol. Cell. Neurosci.* 13, 326–336.
- [15] Chen, J., Butowt, R., Rind, H.B. and von Bartheld, C.S. (2003) *Mol. Cell. Neurosci.* 24, 41–56.
- [16] Schuck, S., Honsho, M., Ekroos, K., Shevchenko, A. and Simons, K. (2003) *Proc. Natl. Acad. Sci. USA* 100, 5795–5800.
- [17] McCabe, J.B. and Berthiaume, L.G. (2001) *Mol. Biol. Cell.* 12, 3601–3617.
- [18] Munro, S. (2003) *Cell* 115, 377–388.